Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Breast cancer
N Harbeck, F Penault-Llorca… - Nature reviews …, 2019 - mayoclinic.elsevierpure.com
Breast cancer is the most frequent malignancy in women worldwide and is curable in~ 70–
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …
[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …
ABSTRACT The 14th St Gallen International Breast Cancer Conference (2015) reviewed
substantial new evidence on locoregional and systemic therapies for early breast cancer …
substantial new evidence on locoregional and systemic therapies for early breast cancer …
[HTML][HTML] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of …
G Curigliano, HJ Burstein, EP Winer, M Gnant… - Annals of …, 2017 - Elsevier
ABSTRACT The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna,
Austria reviewed substantial new evidence on loco-regional and systemic therapies for early …
Austria reviewed substantial new evidence on loco-regional and systemic therapies for early …
[HTML][HTML] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast …
HJ Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant… - Annals of …, 2019 - Elsevier
Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a …
R Bradley, J Braybrooke, R Gray, RK Hills, Z Liu… - The Lancet …, 2022 - thelancet.com
Background For women with early-stage oestrogen receptor (ER)-positive breast cancer,
adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors …
adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors …
Secondary osteoporosis
Osteoporosis is a global public health problem, with fractures contributing to significant
morbidity and mortality. Although postmenopausal osteoporosis is most common, up to 30 …
morbidity and mortality. Although postmenopausal osteoporosis is most common, up to 30 …
Managing osteoporosis in patients on long‐term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research
Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This
ASBMR report provides guidance on BP therapy duration with a risk‐benefit perspective …
ASBMR report provides guidance on BP therapy duration with a risk‐benefit perspective …
[HTML][HTML] Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Early Breast Cancer Trialists' Collaborative Group - The Lancet, 2015 - Elsevier
Background Bisphosphonates have profound effects on bone physiology, and could modify
the process of metastasis. We undertook collaborative meta-analyses to clarify the risks and …
the process of metastasis. We undertook collaborative meta-analyses to clarify the risks and …
[HTML][HTML] ESO–ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)
Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …
disease.•Management of breast cancer in young women requires special considerations …